Gene knockdown studies in breast cancer cells identified the role of CYP2S1 in metabolically inactivating benzothiazoles while induction of CYP1A1 remained crucial for their activation and anti-tumour properties [85]. This evidence concerns the gene CYP2S1 and neoplasm.